SUBSCRIBE
SUBSCRIBE

Boehringer Ingelheim Pharmaceuticals, Inc.

NEWS
Business
Boehringer Focuses on RNA
Boehringer has made a big push into RNA this month.
November 27, 2017
 · 
1 min read
 · 
Karl Thiel
Business
Boehringer, MiNA Therapeutics Forge EUR 307M R&D NASH Tie-Up
Fresh off the heels of a $201M liver disease R&D deal with Dicerna, Boehringer Ingelheim has struck another deal targeting liver disease with MiNA Therapeutics.
November 8, 2017
 · 
2 min read
 · 
Alex Keown
AIDS Drugs Cocktail Better Than Single Nevirapine Dose In Newborns
October 19, 2005
 · 
1 min read
Policy
Pain Drug Mobic Shows Increased Risk - FDA Scientist
October 19, 2005
 · 
1 min read
Policy
US Warns Of Safety Risks Of Boehringer AIDS Drug
October 19, 2005
 · 
1 min read
New Help For Urinary Dysfunction
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
FDA
Boehringer Ingelheim Pharmaceuticals, Inc. Release: FDA Approves Pradaxa® (Dabigatran Etexilate Mesylate) For Treatment And Reduction In The Risk Of Recurrence Of Deep Venous Thrombosis And Pulmonary Embolism
April 7, 2014
 · 
15 min read
Pharm Country
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Pradaxa® (dabigatran etexilate mesylate) Data To Be Presented At American College of Cardiology Scientific Session (ACC.14)
March 25, 2014
 · 
8 min read
Policy
Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company Diabetes Drug Empagliflozin Wins EU Panel’s Backing
March 21, 2014
 · 
5 min read
Drug Development
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Phase III Study Of Dabigatran Etexilate Mesylate Met Primary Endpoint For Six-Month Treatment Of Deep Vein Thrombosis (DVT) And/Or Pulmonary Embolism (PE)
December 17, 2013
 · 
13 min read
Pharm Country
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Long-Term Data Presented At American Heart Association Scientific Sessions Reinforce Safety Profile Of Pradaxa® (dabigatran etexilate mesylate)
November 18, 2013
 · 
12 min read
Business
Boehringer Ingelheim Pharmaceuticals, Inc.'s Jeff Huth Elected as National Pharmaceutical Council’s Chairman of the Board
November 8, 2013
 · 
2 min read
Drug Development
Boehringer Ingelheim Pharmaceuticals, Inc.'s Interferon-Free Hepatitis C Treatment Portfolio Strengthened by Promising Interim Phase 2a Data
November 4, 2013
 · 
9 min read
Pharm Country
Boehringer Ingelheim Pharmaceuticals, Inc. to Present Latest Data from Robust Respiratory Portfolio at American College of Chest Physicians (ACCP) Annual Meeting
October 25, 2013
 · 
10 min read
Drug Development
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Investigational Interferon-Free Regimen Demonstrates Undetectable Hepatitis C Virus in All Patients Reaching End of Treatment in Ongoing Phase 2 Trial
October 8, 2013
 · 
8 min read
Drug Development
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Investigational Interferon-Free Regimen Demonstrates Undetectable Hepatitis C Virus in All Patients Reaching End of Treatment in Ongoing Phase 2 Trial
October 8, 2013
 · 
8 min read
Load More